Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination.
Acetylation
Administration, Intranasal
Animals
BCG Vaccine
/ administration & dosage
Bone Marrow
/ drug effects
Cellular Reprogramming
/ genetics
Female
Gene Expression Regulation
Histones
/ genetics
Immunity, Mucosal
Injections, Intravenous
Interleukin-1beta
/ genetics
Interleukin-6
/ genetics
Lung
/ drug effects
Macaca mulatta
Male
Monocytes
/ drug effects
Mycobacterium tuberculosis
/ immunology
Respiratory Mucosa
/ immunology
Tuberculosis Vaccines
/ administration & dosage
Tuberculosis, Pulmonary
/ genetics
Tumor Necrosis Factor-alpha
/ genetics
BCG
MTBVAC
immunotherapy
innate immunity
non-human primates
trained immunity
tuberculosis
vaccination
vaccine development
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
19 01 2021
19 01 2021
Historique:
received:
30
04
2020
revised:
22
10
2020
accepted:
15
12
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
BCG vaccination can strengthen protection against pathogens through the induction of epigenetic and metabolic reprogramming of innate immune cells, a process called trained immunity. We and others recently demonstrated that mucosal or intravenous BCG better protects rhesus macaques from
Identifiants
pubmed: 33521699
doi: 10.1016/j.xcrm.2020.100185
pii: S2666-3791(20)30240-8
pmc: PMC7817864
doi:
Substances chimiques
BCG Vaccine
0
Histones
0
Interleukin-1beta
0
Interleukin-6
0
MTBVAC vaccine
0
Tuberculosis Vaccines
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100185Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
E.R., E.P., N.A., and C.M. are co-inventors on a patent on a tuberculosis vaccine held by the University of Zaragoza and Biofabri. E.R. and E.P. are employees of Biofabri. J.T. is an employee of the TuBerculosis Vaccine Initiative and an advisor to Biofabri. M.G.N. holds a patent on the inhibition of trained immunity with nanobiologics, and a patent on the stimulation of trained immunity with nanobiologics. M.G.N. is also a scientific founder of Trained Therapeutix and Discovery (TTxD). The remaining authors of the Radboud UMC and the authors from the BPRC declare no competing interests.
Références
Cell. 2018 Nov 29;175(6):1634-1650.e17
pubmed: 30433869
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Lancet Respir Med. 2019 Sep;7(9):757-770
pubmed: 31416768
Science. 2014 Sep 26;345(6204):1251086
pubmed: 25258085
Clin Microbiol Infect. 2019 Dec;25(12):1468-1472
pubmed: 30807849
PeerJ. 2016 Jul 19;4:e2209
pubmed: 27547532
Nature. 2020 Jan;577(7788):95-102
pubmed: 31894150
Nat Commun. 2017 Jul 14;8:16085
pubmed: 28706226
J Clin Invest. 2019 Sep 3;129(9):3482-3491
pubmed: 31478909
Lancet. 1995 Nov 18;346(8986):1339-45
pubmed: 7475776
Lancet Respir Med. 2015 Dec;3(12):953-62
pubmed: 26598141
Nat Rev Microbiol. 2005 Aug;3(8):656-62
pubmed: 16012514
Front Microbiol. 2020 Jan 30;10:3154
pubmed: 32082273
Science. 2016 Apr 22;352(6284):aaf1098
pubmed: 27102489
BMJ. 2016 Oct 13;355:i5170
pubmed: 27737834
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Rev Immunol. 2018 Sep;18(9):575-589
pubmed: 29895826
Front Immunol. 2019 Apr 03;10:684
pubmed: 31001278
Cell Host Microbe. 2012 Aug 16;12(2):223-32
pubmed: 22901542
J Clin Invest. 2018 May 1;128(5):1837-1851
pubmed: 29461976
Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5
pubmed: 29324233
PLoS Pathog. 2020 Apr 2;16(4):e1008404
pubmed: 32240273
Cell Host Microbe. 2020 Aug 12;28(2):322-334.e5
pubmed: 32544459
Tuberculosis (Edinb). 2017 May;104:46-57
pubmed: 28454649
Front Immunol. 2017 Dec 15;8:1803
pubmed: 29326700
BMJ Open. 2020 Feb 28;10(2):e035595
pubmed: 32114478
Immunity. 2017 Apr 18;46(4):549-561
pubmed: 28423336
Clin Infect Dis. 2014 Feb;58(4):470-80
pubmed: 24336911
Nat Methods. 2015 Oct;12(10):963-965
pubmed: 26280331
Nat Rev Immunol. 2020 Jun;20(6):375-388
pubmed: 32132681
Science. 2014 Sep 26;345(6204):1250684
pubmed: 25258083
Mucosal Immunol. 2019 May;12(3):589-600
pubmed: 30874596
Genome Biol. 2008;9(9):R137
pubmed: 18798982
N Engl J Med. 2018 Jul 12;379(2):138-149
pubmed: 29996082
Nat Med. 2019 Feb;25(2):255-262
pubmed: 30664782
Cell. 2018 Jan 11;172(1-2):176-190.e19
pubmed: 29328912
J Infect Dis. 2011 Jul 15;204(2):245-52
pubmed: 21673035
J Infect Dis. 2020 Mar 28;221(8):1342-1350
pubmed: 30958547
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42
pubmed: 22988082
Infect Immun. 2002 Feb;70(2):672-8
pubmed: 11796598
Am Rev Respir Dis. 1973 Mar;107(3):351-8
pubmed: 4632221
F1000Res. 2018 Feb 16;7:199
pubmed: 29568497
Front Immunol. 2019 Nov 01;10:2479
pubmed: 31736945
Expert Rev Vaccines. 2013 Dec;12(12):1431-48
pubmed: 24195481
NPJ Vaccines. 2021 Jan 4;6(1):4
pubmed: 33397991
J Immunol. 2020 Nov 15;205(10):2750-2762
pubmed: 32998983
J Infect Dis. 2019 Aug 30;220(7):1091-1098
pubmed: 31165861
Expert Rev Vaccines. 2017 Jun;16(6):565-576
pubmed: 28447476
Vaccine. 2013 Oct 1;31(42):4867-73
pubmed: 23965219